The release of the LiGHT Trial Study in the April 13, 2019, edition of The Lancet, “Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): A multicentre randomized controlled trail,” changes the course of glaucoma treatment for ophthalmology.1 The study considered the efficacy of Selective Laser Trabeculoplasty (SLT) versus glaucoma eye drops as treatment for patients with open-angle glaucoma or ocular hypertension. The results of the study indicated that SLT should be offered as a first-line treatment for open angle glaucoma and ocular hypertension.